Cell Stem Cell:p53/p21在范可尼氏贫血病中的独特作用

2012-06-17 bo 生物谷

6月7日,Cell Stem Cell杂志在线报道了,p53/p21在范可尼氏贫血中发挥的独特作用。 范可尼氏贫血(FA)是一种遗传性DNA修复缺陷综合征。FA患者常在童年期发生进行性骨髓功能失调(BMF),需要进行同种异体造血干细胞移植。这种BMF的病理机制至今不明。 该研究表明,FA患者的造血干细胞和造血祖细胞(HSPCs)在发生BMF之前就已经显示出严重的缺陷。由于复制的压力和DNA损伤

6月7日,Cell Stem Cell杂志在线报道了,p53/p21在范可尼氏贫血中发挥的独特作用。

范可尼氏贫血(FA)是一种遗传性DNA修复缺陷综合征。FA患者常在童年期发生进行性骨髓功能失调(BMF),需要进行同种异体造血干细胞移植。这种BMF的病理机制至今不明。

该研究表明,FA患者的造血干细胞和造血祖细胞(HSPCs)在发生BMF之前就已经显示出严重的缺陷。由于复制的压力和DNA损伤修复缺陷,FA细胞中p53高度活化。这触发了晚期p21Cdkn1a依赖的G0/G1期阻滞。在多个体内和体外实验模型中(包括人FA及FA样细胞),下调p53可缓解HSPC缺陷。

总之,该研究证实,p53/p21对细胞应激和DNA损伤积累的过分反应在FA患者的HSPC进行性减少过程中发挥着核心作用。这一机制的揭示对临床治疗具有重要意义。(生物谷bioon.com)

 

doi:10.1016/j.cell.2011.10.017
PMC:

PMID:

Bone Marrow Failure in Fanconi Anemia Is Triggered by an Exacerbated p53/p21 DNA Damage Response that Impairs Hematopoietic Stem and Progenitor Cells

Raphael Ceccaldi, Kalindi Parmar, Enguerran Mouly, Marc Delord,et al

Fanconi anemia (FA) is an inherited DNA repair deficiency syndrome. FA patients undergo progressive bone marrow failure (BMF) during childhood, which frequently requires allogeneic hematopoietic stem cell transplantation. The pathogenesis of this BMF has been elusive to date. Here we found that FA patients exhibit a profound defect in hematopoietic stem and progenitor cells (HSPCs) that is present before the onset of clinical BMF. In response to replicative stress and unresolved DNA damage, p53 is hyperactivated in FA cells and triggers a late p21Cdkn1a-dependent G0/G1 cell-cycle arrest. Knockdown of p53 rescued the HSPC defects observed in several in vitro and in vivo models, including human FA or FA-like cells. Taken together, our results identify an exacerbated p53/p21 physiological response to cellular stress and DNA damage accumulation as a central mechanism for progressive HSPC elimination in FA patients, and have implications for clinical care.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798088, encodeId=a8761e9808847, content=<a href='/topic/show?id=0b176811589' target=_blank style='color:#2F92EE;'>#独特作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68115, encryptionId=0b176811589, topicName=独特作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Tue Nov 20 04:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813395, encodeId=1e7a181339569, content=<a href='/topic/show?id=3cfa924456f' target=_blank style='color:#2F92EE;'>#贫血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92445, encryptionId=3cfa924456f, topicName=贫血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Mar 22 14:06:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786021, encodeId=961a1e86021e8, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Mar 04 04:06:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794333, encodeId=f6a01e943337c, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 01 08:06:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868524, encodeId=627918685247d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 03 01:06:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958756, encodeId=21981958e5688, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 06 09:06:00 CST 2013, time=2013-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372337, encodeId=890d13e2337aa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481784, encodeId=20cd1481e84be, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798088, encodeId=a8761e9808847, content=<a href='/topic/show?id=0b176811589' target=_blank style='color:#2F92EE;'>#独特作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68115, encryptionId=0b176811589, topicName=独特作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Tue Nov 20 04:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813395, encodeId=1e7a181339569, content=<a href='/topic/show?id=3cfa924456f' target=_blank style='color:#2F92EE;'>#贫血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92445, encryptionId=3cfa924456f, topicName=贫血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Mar 22 14:06:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786021, encodeId=961a1e86021e8, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Mar 04 04:06:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794333, encodeId=f6a01e943337c, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 01 08:06:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868524, encodeId=627918685247d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 03 01:06:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958756, encodeId=21981958e5688, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 06 09:06:00 CST 2013, time=2013-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372337, encodeId=890d13e2337aa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481784, encodeId=20cd1481e84be, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1798088, encodeId=a8761e9808847, content=<a href='/topic/show?id=0b176811589' target=_blank style='color:#2F92EE;'>#独特作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68115, encryptionId=0b176811589, topicName=独特作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Tue Nov 20 04:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813395, encodeId=1e7a181339569, content=<a href='/topic/show?id=3cfa924456f' target=_blank style='color:#2F92EE;'>#贫血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92445, encryptionId=3cfa924456f, topicName=贫血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Mar 22 14:06:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786021, encodeId=961a1e86021e8, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Mar 04 04:06:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794333, encodeId=f6a01e943337c, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 01 08:06:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868524, encodeId=627918685247d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 03 01:06:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958756, encodeId=21981958e5688, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 06 09:06:00 CST 2013, time=2013-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372337, encodeId=890d13e2337aa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481784, encodeId=20cd1481e84be, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2013-03-04 tulenzi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1798088, encodeId=a8761e9808847, content=<a href='/topic/show?id=0b176811589' target=_blank style='color:#2F92EE;'>#独特作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68115, encryptionId=0b176811589, topicName=独特作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Tue Nov 20 04:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813395, encodeId=1e7a181339569, content=<a href='/topic/show?id=3cfa924456f' target=_blank style='color:#2F92EE;'>#贫血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92445, encryptionId=3cfa924456f, topicName=贫血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Mar 22 14:06:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786021, encodeId=961a1e86021e8, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Mar 04 04:06:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794333, encodeId=f6a01e943337c, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 01 08:06:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868524, encodeId=627918685247d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 03 01:06:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958756, encodeId=21981958e5688, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 06 09:06:00 CST 2013, time=2013-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372337, encodeId=890d13e2337aa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481784, encodeId=20cd1481e84be, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1798088, encodeId=a8761e9808847, content=<a href='/topic/show?id=0b176811589' target=_blank style='color:#2F92EE;'>#独特作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68115, encryptionId=0b176811589, topicName=独特作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Tue Nov 20 04:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813395, encodeId=1e7a181339569, content=<a href='/topic/show?id=3cfa924456f' target=_blank style='color:#2F92EE;'>#贫血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92445, encryptionId=3cfa924456f, topicName=贫血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Mar 22 14:06:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786021, encodeId=961a1e86021e8, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Mar 04 04:06:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794333, encodeId=f6a01e943337c, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 01 08:06:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868524, encodeId=627918685247d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 03 01:06:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958756, encodeId=21981958e5688, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 06 09:06:00 CST 2013, time=2013-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372337, encodeId=890d13e2337aa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481784, encodeId=20cd1481e84be, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1798088, encodeId=a8761e9808847, content=<a href='/topic/show?id=0b176811589' target=_blank style='color:#2F92EE;'>#独特作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68115, encryptionId=0b176811589, topicName=独特作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Tue Nov 20 04:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813395, encodeId=1e7a181339569, content=<a href='/topic/show?id=3cfa924456f' target=_blank style='color:#2F92EE;'>#贫血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92445, encryptionId=3cfa924456f, topicName=贫血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Mar 22 14:06:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786021, encodeId=961a1e86021e8, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Mar 04 04:06:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794333, encodeId=f6a01e943337c, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 01 08:06:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868524, encodeId=627918685247d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 03 01:06:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958756, encodeId=21981958e5688, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 06 09:06:00 CST 2013, time=2013-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372337, encodeId=890d13e2337aa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481784, encodeId=20cd1481e84be, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2013-04-06 维他命
  7. [GetPortalCommentsPageByObjectIdResponse(id=1798088, encodeId=a8761e9808847, content=<a href='/topic/show?id=0b176811589' target=_blank style='color:#2F92EE;'>#独特作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68115, encryptionId=0b176811589, topicName=独特作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Tue Nov 20 04:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813395, encodeId=1e7a181339569, content=<a href='/topic/show?id=3cfa924456f' target=_blank style='color:#2F92EE;'>#贫血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92445, encryptionId=3cfa924456f, topicName=贫血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Mar 22 14:06:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786021, encodeId=961a1e86021e8, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Mar 04 04:06:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794333, encodeId=f6a01e943337c, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 01 08:06:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868524, encodeId=627918685247d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 03 01:06:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958756, encodeId=21981958e5688, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 06 09:06:00 CST 2013, time=2013-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372337, encodeId=890d13e2337aa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481784, encodeId=20cd1481e84be, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2012-06-19 zhishijing
  8. [GetPortalCommentsPageByObjectIdResponse(id=1798088, encodeId=a8761e9808847, content=<a href='/topic/show?id=0b176811589' target=_blank style='color:#2F92EE;'>#独特作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68115, encryptionId=0b176811589, topicName=独特作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Tue Nov 20 04:06:00 CST 2012, time=2012-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813395, encodeId=1e7a181339569, content=<a href='/topic/show?id=3cfa924456f' target=_blank style='color:#2F92EE;'>#贫血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92445, encryptionId=3cfa924456f, topicName=贫血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Mar 22 14:06:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786021, encodeId=961a1e86021e8, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Mar 04 04:06:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794333, encodeId=f6a01e943337c, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 01 08:06:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868524, encodeId=627918685247d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Feb 03 01:06:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958756, encodeId=21981958e5688, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Apr 06 09:06:00 CST 2013, time=2013-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372337, encodeId=890d13e2337aa, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481784, encodeId=20cd1481e84be, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Jun 19 11:06:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]

相关资讯

Biol Psychiat:D-环丝氨酸有助治疗创伤后应激障碍

近日,科学家们发现D-环丝氨酸能加强现有的创伤后应激障碍的治疗方法的治疗功效,新的研究报告发表在Biological Psychiatry杂志上。 创伤后应激障碍(PTSD)是最常见的生活事件。创伤后应激障碍的第一线治疗是暴露疗法,就是让病人在一个安全的环境面对他们的恐惧。虽然这是一种有效的治疗,但仍然会出现许多治疗后的症状,因此其成功率并不高。 在努力改进现有的治疗方法的基础上,本周发表在B

PLoS Comput Biol:艾滋病毒耐药性的起源问题

近日,哈佛大学的科学家们发现在少数艾滋病患者预先存在的突变可能导致病毒产生耐药性。这一发现特别重要,因为虽然研究人员早就知道艾滋病毒可以对某些药物产生耐药性,但我们一直不理解该病毒是否靠预先已经存在的突变来产生耐药性,相关研究论文发表在PLoS Computational Biology杂志上。 Pennings收集了26个临床试验的数据收集。这些患者接受NNRTI药物的治疗以阻止病毒的繁殖。然

J Biol Chem:研究者开发出治疗II型糖尿病的新药

治疗II型糖尿病的药物可以促使体重增加、骨折以及心血管疾病,但是近日,来自美国华盛顿大学医学院的研究者研究表明,一种研究药物的使用可以导致小鼠增加对胰岛素的敏感性,而没有任何副作用。这项研究刊登在了国际杂志Journal of Biological Chemistry上,新研究将为治疗胰岛素耐受性以及糖尿病提供新的分子靶点。 当前的糖尿病用药可以激活一种受体,进而提高对胰岛素的敏感性,但是也会有

PNAS:寒冷可以激活棕色脂肪燃烧 为减肥提供良机

棕色脂肪 近日,来自乔斯林糖尿病中心的研究者通过研究发现,一种对人体有益处的脂肪会在低温下被激活,研究者们同时也发现这种脂肪并不会被药物麻黄碱所激活。相关研究成果刊登在了近日的国际杂志PNAS上。文章中所提到的这种脂肪是棕色脂肪,这种脂肪一旦激活,可以在机体内燃烧卡路里并且帮助机体抵御肥胖。 研究者Aaron Cypess表示,我们可以通过提供类似制冷的因子来激活棕色脂肪,进而寻找到抵御肥胖的

Nature:哺乳动物细胞的生物计算器开发为病人带来福利

研究者重新编程了哺乳动物的细胞以便像袖珍计算机一样使细胞执行逻辑运算的能力。 (Credit: J. Kuster / ETH Zurich) 近日,来自苏黎世联邦理工学院的研究者重新编程了哺乳动物的细胞以便像袖珍计算机一样使细胞执行逻辑运算的能力。这些细胞欠缺一种最为复杂的基因调控网络,于是研究者构架了不同的基因调控网络使其可以进行运算,基于此,细胞可以进行特殊的代谢过程。科学家用生物组分开发

FASEB J:研究人员发现大脑调节肾功能的信号

近日,波士顿大学医学院(BUSM)的研究人员发现大脑中调节肾脏排泄钠的信号通路。这一发现刊登在Journal of the Federation of American Societies for Experimental Biology杂志上。   高血压或慢性血压高,影响了三分之一的成年人,能显着增加心血管疾病的风险和死亡率。高血压患者中约50%是对盐敏感的,表现为盐摄入后血压会